Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Barinthus BiotherapeuticsSTU:2AB -0.41%14 Price-to-Tangible-Book is 0.51 as of Aug. 11, 2026, which is 14% below its 10-year median of 0.59. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.96. The stock has 1 warning sign investors should review. Among 1,142 Biotechnology companies, Barinthus Biotherapeutics ranks better than 94.66% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Barinthus Biotherapeutics Price-to-Tangible-Book Related Terms
Barinthus Biotherapeutics Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs CRVO, ALGS, TVRD: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Barinthus Biotherapeutics (STU:2AB) has a Price-to-Tangible-Book of 0.51 as of Aug. 11, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Barinthus Biotherapeutics and its competitors. This is 14% below median its historical median of 0.59. Over the past decade, Barinthus Biotherapeutics' Price-to-Tangible-Book has ranged from 0.38 to 2.31. According to the industry distribution chart, Barinthus Biotherapeutics ranks #61 out of 1142 companies in the Biotechnology industry, placing it in the top 5.3%.
Is Barinthus Biotherapeutics' Price-to-Tangible-Book too high?
Barinthus Biotherapeutics' current Price-to-Tangible-Book of 0.51 is 14% below median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 2.31. The Biotechnology industry median Price-to-Tangible-Book is 3.26. Barinthus Biotherapeutics' value of 0.51 is 84.4% below this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #61 out of 1142 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Price-to-Tangible-Book compare to CRVO and ALGS?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #61 out of 1142 companies for Price-to-Tangible-Book. This places Barinthus Biotherapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.26. Barinthus Biotherapeutics' value of 0.51 is 84.4% below this benchmark. Historically, Barinthus Biotherapeutics' own Price-to-Tangible-Book has ranged from 0.38 to 2.31 over the past decade. While the company's 10-year median is 0.59 vs. the industry median of 3.26, Barinthus Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,142 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current Price-to-Tangible-Book of 0.51 is 84.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Price-to-Tangible-Book is 0.51, which is 14% below median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Price-to-Tangible-Book of 0.51. The stock's GF Value™ is €0.96, compared to a current price of €0.48 — trading 50% below its estimated fair value. The current Price-to-Tangible-Book is 0.51, which is 14% below median its 10-year median of 0.59 and 84.4% below the Biotechnology industry median of 3.26. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Price-to-Tangible-Book is 0.51 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.48 is trading 50% below its estimated GF Value™ of €0.96.
Key valuation signals for STU:2AB:
Price-to-Tangible-Book: 0.51 (14% below median its 10-year median of 0.59)
GF Value™: €0.96 vs. price of €0.48 (50% below fair value)
Industry Position: 84.4% below the Biotechnology median (#61 of 1142)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
